Daniele Santini | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Human equilibrative nucleoside transporter 1 as a predictor of efficacy to gemcitabine in angiosarcoma and leiomyosarcoma	JOURNAL OF CLINICAL ONCOLOGY	2016
Biological effects of cabozantinib on bone microenvironment	JOURNAL OF CLINICAL ONCOLOGY	2016
Bone-Targeted Agents	Bone Metastases from Prostate Cancer	2016
Bone-Targeted Agents	Bone Metastases from Prostate Cancer	2016
RE: Regorafenib Also Can Cause Osteonecrosis of the Jaw	JOURNAL OF THE NATIONAL CANCER INSTITUTE	2016
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis	ONCOTARGET	2016
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib	ONCOTARGET	2016
Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma	CANCER CHEMOTHERAPY AND PHARMACOLOGY	2016
Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study	ONCOTARGET	2016
Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR"	CANCER TREATMENT REVIEWS	2016
Adjuvant bisphosphonates in early breast cancer. Consensus guidance for clinical practice from a European Panel	ANNALS OF ONCOLOGY	2016
Procalcitonin as diagnostic marker of infection in solid tumors patients with fever	SCIENTIFIC REPORTS	2016
Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology	EXPERT OPINION ON DRUG SAFETY	2016
Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study	PLOS ONE	2016
Re: Idir Ouzaid and Karim Bensalah. Results of the First Trial Assessing Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma Do Not reASSURE. Eur Urol 2015;68:542-3	EUROPEAN UROLOGY	2016
Randomized Trial of Low-Dose Morphine Versus Weak Opioids in Moderate Cancer Pain	JOURNAL OF CLINICAL ONCOLOGY	2016
Corrigendum: Natural History of Non-Small-Cell Lung Cancer with Bone Metastases	SCIENTIFIC REPORTS	2016
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis	ONCOTARGET	2016
Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma	CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY	2016
Treatment of advanced renal-cell carcinoma	NEW ENGLAND JOURNAL OF MEDICINE	2016